SIM2: Its Prognostic Significance and Oncogenic Role in Endometrial Carcinoma

References

• Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412–1428. doi:10.1016/s0140-6736(22)00323-3
   PubMed Web of Science ®Google Scholar
• Gheorghe AS, Dumitrescu EA, Komporaly IA, Mihăilă RI, Lungulescu CV, Stănculeanu DL. New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: a Year in Review. Curr Oncol. 2022;29(4):2835–2847. doi:10.3390/curroncol29040231
   PubMed Web of Science ®Google Scholar
• Tossetta G, Marzioni D. Targeting the NRF2/KEAP1 pathway in cervical and endometrial cancers. Eur J Pharmacol. 2023;941:175503. doi:10.1016/j.ejphar.2023.175503
   PubMed Web of Science ®Google Scholar
• Guo F, Zhang H, Jia Z, Cui M, Tian J. Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer. Am j Cancer Res. 2018;8(7):1317–1331.
   PubMed Web of Science ®Google Scholar
• Gu B, Shang X, Yan M, et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. Gynecologic Oncol. 2021;161(2):573–580. doi:10.1016/j.ygyno.2021.01.036
   PubMed Web of Science ®Google Scholar
• Tamaoki M, Komatsuzaki R, Komatsu M, et al. Multiple roles of single-minded 2 in esophageal squamous cell carcinoma and its clinical implications. Cancer Sci. 2018;109(4):1121–1134. doi:10.1111/cas.13531
   PubMed Web of Science ®Google Scholar
• Nakamura K, Komatsu M, Chiwaki F, et al. SIM2l attenuates resistance to hypoxia and tumor growth by transcriptional suppression of HIF1A in uterine cervical squamous cell carcinoma. Sci Rep. 2017;7(1):14574. doi:10.1038/s41598-017-15261-4
   PubMedGoogle Scholar
• Kwak HI, Gustafson T, Metz RP, Laffin B, Schedin P, Porter WW. Inhibition of breast cancer growth and invasion by single-minded 2s. Carcinogenesis. 2007;28(2):259–266. doi:10.1093/carcin/bgl122
   PubMed Web of Science ®Google Scholar
• Aleman MJ, DeYoung MP, Tress M, Keating P, Perry GW, Narayanan R. Inhibition of Single Minded 2 gene expression mediates tumor-selective apoptosis and differentiation in human colon cancer cells. Proc Natl Acad Sci USA. 2005;102(36):12765–12770. doi:10.1073/pnas.0505484102
   PubMed Web of Science ®Google Scholar
• DeYoung MP, Tress M, Narayanan R. Down’s syndrome-associated Single Minded 2 gene as a pancreatic cancer drug therapy target. Cancer Lett. 2003;200(1):25–31. doi:10.1016/s0304-3835(03)00409-9
   PubMed Web of Science ®Google Scholar
• Halvorsen OJ, Rostad K, Øyan AM, et al. Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer. Clin Cancer Res. 2007;13(3):892–897. doi:10.1158/1078-0432.Ccr-06-1207
   PubMed Web of Science ®Google Scholar
• Launonen KM, Paakinaho V, Sigismondo G, et al. Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells. Oncogene. 2021;40(27):4567–4579. doi:10.1038/s41388-021-01887-2
   PubMed Web of Science ®Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. doi:10.1126/science.1260419
   PubMed Web of Science ®Google Scholar
• Oughtred R, Stark C, Breitkreutz BJ, et al. The BioGRID interaction database: 2019 update. Nucleic Acids Res. 2019;47(D1):D529–d541. doi:10.1093/nar/gky1079
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Yang X, Li X, Cheng Y, et al. Comprehensive Analysis of the Glycolysis-Related Gene Prognostic Signature and Immune Infiltration in Endometrial Cancer. Front Cell Develop Biol. 2021;9:797826. doi:10.3389/fcell.2021.797826
   PubMed Web of Science ®Google Scholar
• Liew PL, Huang RL, Wu TI, et al. Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings. Clin epigenetics. 2019;11(1):170. doi:10.1186/s13148-019-0765-3
   PubMed Web of Science ®Google Scholar
• Patel MV, Shen Z, Rodriguez-Garcia M, Usherwood EJ, Tafe LJ, Wira CR. Endometrial Cancer Suppresses CD8+ T Cell-Mediated Cytotoxicity in Postmenopausal Women. Front Immunol. 2021;12:657326. doi:10.3389/fimmu.2021.657326
   PubMed Web of Science ®Google Scholar
• Golia D’Augè T, Cuccu I, Santangelo G, et al. Novel Insights into Molecular Mechanisms of Endometrial Diseases. Biomolecules. 2023;13(3):499. doi:10.3390/biom13030499
   PubMed Web of Science ®Google Scholar
• Cao W, Ma X, Fischer JV, Sun C, Kong B, Zhang Q. Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomarker Res. 2021;9(1):49. doi:10.1186/s40364-021-00301-z
   PubMed Web of Science ®Google Scholar
• Bogani G, Chiappa V, Lopez S, et al. Radiomics and Molecular Classification in Endometrial Cancer (The Rome Study): a Step Forward to a Simplified Precision Medicine. Healthcare. 2022;10(12):2464. doi:10.3390/healthcare10122464
   Web of Science ®Google Scholar
• Lefebvre TL, Ueno Y, Dohan A, et al. Development and Validation of Multiparametric MRI-based Radiomics Models for Preoperative Risk Stratification of Endometrial Cancer. Radiology. 2022;305(2):375–386. doi:10.1148/radiol.212873
   PubMed Web of Science ®Google Scholar
• Lu B, Asara JM, Sanda MG, Arredouani MS. The role of the transcription factor SIM2 in prostate cancer. PLoS One. 2011;6(12):e28837. doi:10.1371/journal.pone.0028837
   PubMed Web of Science ®Google Scholar
• Arredouani MS, Lu B, Bhasin M, et al. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res. 2009;15(18):5794–5802. doi:10.1158/1078-0432.Ccr-09-0911
   PubMed Web of Science ®Google Scholar
• Scribner KC, Behbod F, Porter WW. Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s). Oncogene. 2013;32(21):2631–2639. doi:10.1038/onc.2012.286
   PubMed Web of Science ®Google Scholar
• DeYoung MP, Tress M, Narayanan R. Identification of Down’s syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors. Proc Natl Acad Sci USA. 2003;100(8):4760–4765. doi:10.1073/pnas.0831000100
   PubMed Web of Science ®Google Scholar
• Bersten DC, Sullivan AE, Peet DJ, Whitelaw ML. bHLH-PAS proteins in cancer. Nat Rev Cancer. 2013;13(12):827–841. doi:10.1038/nrc3621
   PubMed Web of Science ®Google Scholar
• Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 2018;15(6):353–365. doi:10.1038/s41571-018-0002-6
   PubMed Web of Science ®Google Scholar
• Tao MH, Freudenheim JL. DNA methylation in endometrial cancer. Epigenetics. 2010;5(6):491–498. doi:10.4161/epi.5.6.12431
   PubMed Web of Science ®Google Scholar
• Xu T, Ding H, Chen J, et al. Research Progress of DNA Methylation in Endometrial Cancer. Biomolecules. 2022;12(7):938. doi:10.3390/biom12070938
   PubMed Web of Science ®Google Scholar
• Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int j Cancer. 2001;91(1):22–26. doi:10.1002/1097-0215(20010101)91:1<22::aid-ijc1002>3.0.co;2-s
   PubMed Web of Science ®Google Scholar
• Arafa M, Kridelka F, Mathias V, et al. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology. 2008;53(5):525–532. doi:10.1111/j.1365-2559.2008.03147.x
   PubMed Web of Science ®Google Scholar
• Hsu YT, Gu F, Huang YW, et al. Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clin Cancer Res. 2013;19(22):6272–6285. doi:10.1158/1078-0432.Ccr-13-1734
   PubMed Web of Science ®Google Scholar
• Tang J, Tian X, Min J, Hu M, Hong L. RPP40 is a prognostic biomarker and correlated with tumor microenvironment in uterine corpus endometrial carcinoma. Front Oncol. 2022;12:957472. doi:10.3389/fonc.2022.957472
   PubMed Web of Science ®Google Scholar
• Weijiao Y, Fuchun L, Mengjie C, et al. Immune infiltration and a ferroptosis-associated gene signature for predicting the prognosis of patients with endometrial cancer. Aging. 2021;13(12):16713–16732. doi:10.18632/aging.203190
   PubMedGoogle Scholar
• Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15(5):458–469. doi:10.1038/s41423-018-0004-4
   PubMed Web of Science ®Google Scholar
• Perez LG, Kempski J, McGee HM, et al. TGF-β signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer. Nat Commun. 2020;11(1):2608. doi:10.1038/s41467-020-16363-w
   PubMed Web of Science ®Google Scholar
• Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(6):1141–1149. doi:10.1182/blood-2009-03-208249
   PubMed Web of Science ®Google Scholar
• Wang J, Li R, Cao Y, et al. Intratumoral CXCR5(+)CD8(+)T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer. Nat Commun. 2021;12(1):3080. doi:10.1038/s41467-021-23356-w
   PubMed Web of Science ®Google Scholar
• Zou Q, Wang X, Ren D, et al. DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. J ImmunoTherapy Cancer. 2021;9(9):56.
   Web of Science ®Google Scholar
• Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res. 2004;10(13):4450–4456. doi:10.1158/1078-0432.Ccr-0732-3
   PubMed Web of Science ®Google Scholar
• Palomero J, Panisello C, Lozano-Rabella M, et al. Biomarkers of tumor-reactive CD4(+) and CD8(+) TILs associate with improved prognosis in endometrial cancer. J ImmunoTherapy Cancer. 2022;10(12).
   PubMed Web of Science ®Google Scholar
• Janssen JBE, Medema JP, Gootjes EC, Tauriello DVF, Verheul HMW. Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. Cancer Treat Rev. 2022;109:102433. doi:10.1016/j.ctrv.2022.102433
   PubMed Web of Science ®Google Scholar
• van Gool IC, Eggink FA, Freeman-Mills L, et al. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clin Cancer Res. 2015;21(14):3347–3355. doi:10.1158/1078-0432.Ccr-15-0057
   PubMed Web of Science ®Google Scholar